 |
|
|
| |
Addressing Barriers to Hepatitis C Virus (HCV) Elimination: Real-World Outcomes in Historically Underserved Patients With Chronic HCV Infection Treated With Glecaprevir/Pibrentasvir
|
| |
| |
AASLD 2019 Nov 8-12 Boston
Reported by Jules Levin
Pietro Lampertico1, Markus Peck-Radosavljevic2, Mark Bondin3, Wodzimierz Mazur4, Lorenzo Magenta5, Juliette Foucher6, Ariel Porcalla3, Eric Crown3, Yash Jalundhwala3, Zhenzhen Zhang3, Konstantinos Mimidis7, Rawi Hazzan8, Nuno Marques9, Stefan Bourgeois10
1CRC "AM e A Migliavacca" Center for Liver Diseases, Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy; 2Department of Internal Medicine and Gastroenterology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria; 3AbbVie Inc., North Chicago, Illinois, United States; 4Clinical Department of Infectious Diseases, Medical University of Silesia, Katowice, Poland; 5Epatocentro Ticino, Lugano, Switzerland; 6Hôpital du Haut-Lévêque, Pessac, France; 7First Department of Internal Medicine, Democritus University of Thrace Medical School, Alexandroupolis, Greece; 8Emek Medical Center, Afula, Israel; 9Infectious Diseases Service, Hospital Garcia de Orta EPE, Almada, Portugal; 10Department of Gastroenterology and Hepatology, ZNA Antwerp, Antwerp, Belgium
|
| |
|
|
|
|
|
